Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2010-05-04 | Gil Price, M.D. 47,500 Fees Earned or Paid in Cash, 5,500 Stock Awards, 18,592 Option Awards, Total 71,592 |
| 2011-05-20 | Gil Price, M.D., has served as a member of our board of directors since October 2007. He also serves as the chairman of the nominating and corporate governance committee and as a member of the audit committee. |
| 2012-06-13 | Gil Price, M.D., has served as a member of our board of directors since October 2007. He also serves as the chairman of the compensation committee and as a member of the nominating and corporate governance committee. |
| 2013-04-30 | Gil Price, M.D., 57, Group I Director. He serves as the chairman of the compensation committee and as a member of the nominating and corporate governance committee. Compensation table shows total $94,671 in 2012. |
| 2014-04-30 | Gil Price, M.D., Group I Director; age 58; chairman of nominating and corporate governance committee; member of compensation committee; total annual compensation $556,707. |
| 2015-04-30 | Gil Price, M.D., has served as a member of our Board since October 2007. He also serves as the chairman of the nominating and corporate governance committee and as a member of the compensation committee. ... The following table sets forth compensation information for our non-employee directors for 2014... Gil Price, M.D. 64,000 29,030 315,063 408,093 |
| 2016-05-31 | Gil Price, M.D., has served as a member of our Board since October 2007 when he was added to the Board to, among other things, advise on the early regulatory process for potential biopharmaceutical product candidates. With the NDA for eteplirsen having been completed and filed, Dr. Price plans to complete his term as Director and after the Annual Meeting will focus on and pursue other interests and opportunities. Therefore, Dr. Price is not standing for reelection and will not be a member of the Board or its committees after the Annual Meeting. He currently serves on the Compensation Committee and the Audit Committee. |
Data sourced from SEC filings. Last updated: 2025-12-07